Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 02:27:53 2024-04-29 pm EDT			5-day change	1st Jan Change
0.175 ^CAD	0.00%		-2.78%	+20.69%

Apr. 03	Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	CI
Apr. 03	Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	CI

Awakn Life Sciences Corp. Reports Earnings Results for the Full Year Ended January 31, 2023

April 27, 2023 at 05:17 pm EDT

Awakn Life Sciences Corp. reported earnings results for the full year ended January 31, 2023. For the full year, the company reported revenue was CAD 1.5 million compared to CAD 0.236037 million a year ago.

Net loss was CAD 9.14 million compared to CAD 15.95 million a year ago. Basic loss per share from continuing operations was CAD 0.36 compared to CAD 0.73 a year ago.

Latest news about Awakn Life Sciences Corp.

Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	Apr. 03	CI
Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	Apr. 02	CI
Awakn Life Sciences Corp. Designates Program AWKN-002 for Alcohol Use Disorder in the US Market	Jan. 24	CI
Awakn Life Sciences Corp. Enters Global Licensing Agreement with LTS Lohmann Therapie-Systeme AG	Dec. 20	CI
Awakn Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Dec. 14	CI
Awakn Life Sciences Corp. Receives Clinical Trial Authorization from the Medicines and Healthcare Products Regulatory Agency and Health Research Authority in the UK for a Phase III Clinical Trial for its Lead Program AWKN-P001 for the Treatment of Severe Alcohol Use Disorder	Nov. 15	CI
Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study	23-10-04	CI
Awakn Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-14	CI
Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001	23-09-06	CI
The management acquired Awakn Clinics Trondheim and Awakn Clinics Oslo from Awakn Life Sciences Corp..	23-07-31	CI
Awakn Via Amitis Ltd acquired Awakn London Limited from Awakn Life Sciences Corp..	23-07-04	CI
Awakn Life Sciences Corp. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-14	CI
Awakn Life Sciences Corp. Reports Earnings Results for the Full Year Ended January 31, 2023	23-04-27	CI
Awakn Life Sciences Corp. Auditor Raises 'Going Concern' Doubt	23-04-26	CI
Awakn Life Sciences Corp. announced that it expects to receive CAD 3 million in funding	23-04-25	CI
Awakn Life Sciences Corp. Signs Collaboration Agreement with University of Exeter for Upcoming Phase Iii Trial	23-04-18	CI
Awakn Life Sciences Corp. Signs Its Fourth Licensing Partnership Agreement with Ken Starr MD Wellness Group	23-02-28	CI
Awakn Life Sciences Corp. Signs its First Licensing Partnership Agreement in Europe	23-02-21	CI
Awakn Life Sciences Corp. Announces the Opening of Its Fourth Clinic	23-02-14	CI
Awakn Life Sciences Initiates Feasibility Study for Mdma Using Catalent's Zydis Orally Disintegrating Tablet Technology	23-02-09	CI
Awakn Life Sciences Corp. Grants Fast-Track Designation from Uk Regulator for Ketamine-Assisted Therapy for Alcohol Use Disorder	23-02-07	CI
Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-Ketamine to Assess Dissociative Effect	23-01-24	CI
Awakn Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	22-12-15	CI
Awakn Life Sciences Corp. Announces the Signing of A 5-Year Lease to Open Awakn Clinics Trondheim	22-12-01	CI
Awakn Life Sciences Corp. Announces Location for Larger Oslo Clinic Expansion Begins with New Awakn Clinics Oslo	22-11-23	CI

Chart Awakn Life Sciences Corp.

Duration

Period

More charts

Company Profile

Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and commercializing of therapeutics to treat addiction with a focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe. The Company operates in the United Kingdom (UK), Ireland and Canada.

Sector

Biotechnology & Medical Research

Calendar

2024-06-11 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
AWAKN LIFE SCIENCES CORP.	+20.69%	5.07M
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+47.70%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research